Connect Biopharma (Nasdaq: CNTB) is a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research. With operations and expertise in China, the United States and Australia and clinical development activities in those geographies as well as Europe, Connect Biopharma is building a rich pipeline of internally designed, wholly owned small molecules and antibodies targeting several aspects of T cell biology.
Our core expertise is in the use of functional cellular assays with T cells to screen and discover potent drug candidates against immune targets. Our two most advanced clinical-stage programs include highly differentiated product candidates against validated targets.
To find out more about Connect Biopharma and opportunities to join us, please visit our website.
Our core expertise is in the use of functional cellular assays with T cells to screen and discover potent drug candidates against immune targets. Our two most advanced clinical-stage programs include highly differentiated product candidates against validated targets.
To find out more about Connect Biopharma and opportunities to join us, please visit our website.
Location: China, Jiangsu, Suzhou City
Employees: 51-200
Total raised: $325M
Founded date: 2012
Investors 6
| Date | Name | Website |
| - | LAV | lavfund.co... |
| - | RA Capital... | racap.com |
| - | Qiming Ven... | qimingvent... |
| - | HBM Partne... | hbmpartner... |
| - | Qiming Ven... | qimingvc.c... |
| - | Northern L... | nlvc.com |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 01.12.2020 | - | $135M | - |
| 24.08.2020 | Series C | $115M | Qiming Ven... |
| 03.01.2019 | Series B | $55M | Qiming Ven... |
| 25.01.2017 | Series A | $20M | Qiming Ven... |
Mentions in press and media 17
| Date | Title | Description |
| 09.02.2023 | Connect Biopharma Reports CBP-201 Global Phase 2 Asthma Trial Achieves Full Enrollment | Connect Biopharma Holdings Limited (NASDAQ:CNTB)SAN DIEGO, USA, February 9, 2023 /EINPresswire.com/ -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a global clinical-stage biopharmaceutical company d... |
| 02.12.2022 | Connect Biopharma Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement | SAN DIEGO and TAICANG, SUZHOU, China, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited CNTB (Connect Biopharma or the Company), a global clinical-stage biopharmaceutical company developing T cell-driven therapies to trea... |
| 01.12.2020 | Connect Biopharma Holdings Limited announced that it has received $134.999527 million in funding from a group of investors | On December 1, 2020, Connect Biopharma Holdings Limited (NasdaqGM:CNTB) closed the transaction. The company issued 4,744,341 Series C redeemable convertible preferred shares for gross proceeds of $29,999,890 in second tranche closing. The c... |
| 27.08.2020 | Connect Biopharma Completes $115 Million Series C Financing, Qiming Participates | - |
| 25.08.2020 | Connect Biopharma adds $115M to the pot as it eyes rivalry with Dupixent | While Sanofi and Regeneron’s blockbuster Dupixent racks up the sales, more and more biotechs want a piece of the action. Sponsored by Agilent Technologies How would you like to win free bench space at Lab Central for one scientist for an en... |
| 25.08.2020 | Connect Biopharma closes $115m in Series C round led by RA Capital | Premium US and China-based clinical-stage biopharmaceutical firm Connect Biopharma on Monday announced the completion of a $115-million Series C round of financing led by new investor RA Capital Management, a Boston-based multi-stage invest... |
| 25.08.2020 | Connect Biopharma nabs $115M Series C | Connect Biopharma has secured $115 million in a round led by new investor RA Capital Management. Other new investors in the round included Lilly Asia Ventures, Boxer Capital and HBM Healthcare Investments, with existing backer Qiming Ventur... |
| 25.08.2020 | Connect Biopharma adds $115M to the pot as it eyes rivalry with Dupixent | While Sanofi and Regeneron’s blockbuster Dupixent racks up the sales, more and more biotechs want a piece of the action. One of them, China-based Connect Biopharma, just got off a $115 million series C round to try to do just that. Backed b... |
| 24.08.2020 | Connect Biopharma Finds $115M More | San Diego-based Connect Biopharma, which is developing biopharmaceuticals for treating atopic dermatitis and ulerative colitis, has raised $115M in a Series C funding, the company announced Monday morning. According to the company, the roun... |
| 24.08.2020 | Clinical-Stage Biopharmaceutical Company Connect Biopharma Raises $115 Million | Connect Biopharma — a clinical-stage biopharmaceutical company focused on identifying and developing potent and specific immune modulating molecules — announced that it has raised $115 million in Series C funding Connect Biopharma — a clini... |
Show more